The Food and Drug Administration recently approved DAXXIFY, an injectable medication that reduced the appearance of frown lines between the brows for about six months.
According to the maker of the new treatment, Revance Therapeutics, injections into worry lines lasted longer than other products on the market.
Like Botox, Dysport, Xeomin, and Jeuveau, the new treatment is a botulinum toxin/neuromodulator that essentially freezes wrinkles.
In studies submitted to the F.D.A., the treatment far exceeded the effect of a placebo, with about 80 percent of the treatment providers seeing no or mild facial lines between the brow at four months after injection and about half seeing the effect through six months.
DAXXIFY has a safety profile similar to other neuromodulators with no serious treatment related adverse events reported in clinical trial.
We expect DAXXIFY to be available in the near future. Stay tuned for future announcements.
